Lisa Wyman

Lisa is head of technical operations at Generate:Biomedicines, leading multi-faceted teams across CMC, technical development, quality, and supply operations to build out Generate’s global technical operations organization to support the Company’s pursuit of a broad portfolio of medicines. 

Most recently, Lisa served as the senior vice president of technical operations and quality at Acceleron, where she helped to transform the enterprise from a research and development-focused company to a fully integrated biotech, which led to the eventual sale of the company to Merck & Co. in 2021 for over $11 billion. She led the CMC strategy for the accelerated development of sotatercept for pulmonary arterial hypertension and supported the launch of Acceleron’s first commercial product ReblozylÆ. Lisa has experience working with global regulatory agencies, GxP quality management systems, and scaling up manufacturing for clinical-stage companies.

Before joining Acceleron, Lisa had roles of increasing responsibility at Mersana Therapeutics, Shire, and Boston Scientific.

She has received several awards, including a Life Sciences Voice Top Industry Leader, Advancement of Women in Compliance Mentor of the Year Finalist, Boston Business Journal’s 40 Under 40 Winner, and Control Engineering and Plant Engineering Magazine’s Engineering Leader.

Lisa graduated from Ithaca College with a bachelor’s degree in biology and earned her master’s of science degree in engineering management from Tufts University.